RHD
Blood group Rh
As of the edition of 20 October 2026, RHD (blood group Rh, UniProt Q02161) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q02161
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Disease areas
- Blood and lymph; Immune system
- Registered trials of its drugs
- 2
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Roledumab | Went quiet | Phase 2 | none listed |
| Rozrolimupab | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Laboratoire français de Fractionnement et de Biotechnologies | Route A |
| Symphogen A/S | Route A |
The other 0 companies at RHD
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at RHD, ranked, with the facts behind eachRequest access. Nothing is shown until you do.